14.1 Antineoplastic Infusion Therapy

Why antineoplastic infusion is a CRNI high-stakes domain

Domain 3C Antineoplastic Therapy (September 2025 outline) expects infusion nurses to administer cytotoxic and related anticancer infusions with zero tolerance for preventable harm. Errors here produce tissue necrosis, anaphylaxis, wrong-route disasters, occupational exposure, and delayed life-saving treatment. This section teaches the safety architecture: drug tissue class → access device → PPE/handling → verification → monitoring → emergency response.

Quick Answer: Know vesicant / irritant / nonvesicant tissue risk. Prefer central access for many continuous vesicants. Handle hazardous drugs per USP <800> principles with PPE and often CSTDs. Perform independent double-checks. For extravasation: stop, leave catheter temporarily if protocol requires aspirate, mark site, notify, give antidote/specific measures per protocol. For hypersensitivity (taxanes, platinum): stop infusion, call for help, support ABCs, give ordered emergency meds. Protect neutropenic patients around nadir.

Vesicant, irritant, and nonvesicant—tissue injury taxonomy

Tissue risk classification drives device selection, site surveillance intensity, and extravasation kits.

Exam principle: Classification is about local tissue destruction potential, not about whether the drug is “strong chemo.” Some agents can be both systemically hazardous and locally vesicant. Always confirm the specific drug’s known risk with current institutional hazardous-drug and extravasation references—not memory from a single old list.

Common teaching examples (high-level; lists evolve with formulary):

• Classic vesicants often include anthracyclines (e.g., doxorubicin), vinca alkaloids (e.g., vincristine, vinblastine), and some others designated by policy.
• Irritants may include agents that burn or cause chemical phlebitis without full necrosis.
• Nonvesicants still demand correct route, rate, and monitoring.

Never give vinca alkaloids intrathecally—wrong-route vincristine is a catastrophic, often fatal error. Intrathecal medications have separate verification pathways; CRNI expects absolute route discipline.

Access device selection for chemotherapy

Central access preferred or required

Many continuous vesicant infusions and multi-day regimens are ordered via central venous access (PICC, tunneled CVC, implanted port) because:

• Larger, high-flow veins dilute the drug rapidly.
• Risk of peripheral extravasation over hours is unacceptably high.
• Ports and dedicated oncology lines support repeated cycles with better vein preservation.

Peripheral short catheters—when and why caution

Peripheral IVs may be used for selected short infusions of nonvesicants or carefully selected agents per protocol, but:

• Avoid sites over joints, in limbs with compromised circulation/lymphatics (e.g., post-mastectomy side restrictions), or with poor blood return.
• Confirm blood return and free flow before and during vesicant administration when peripheral route is used under protocol.
• Continuous peripheral vesicant therapy is generally not preferred—escalate device concerns before hang.

Midlines and “almost central” traps

Midline catheters terminate in peripheral veins, not the central vena cava. Do not treat a midline as a central line for continuous vesicant therapy. Match the catheter tip location and device type to the drug’s risk profile and order.

Blood return and site checks during vesicants

For vesicant administration:

1. Verify patency and blood return per policy before starting.
2. Educate the patient to report burning, stinging, swelling, or pain immediately.
3. Inspect the site frequently—do not rely only on the pump’s “no occlusion” status.
4. If infiltration/extravasation is suspected: stop the infusion immediately.

Hazardous-drug handling: USP <800> principles and CSTDs

Antineoplastics are hazardous drugs. Occupational exposure routes include dermal contact, inhalation of aerosols/vapors, and incidental ingestion from contaminated surfaces.

USP <800> mindset (nursing actions)

USP <800> sets standards for handling hazardous drugs across the continuum (receipt through disposal). Infusion nurses operationalize principles such as:

Closed-system transfer devices (CSTDs)

CSTDs mechanically prevent environmental contamination during transfer and administration. When policy requires CSTDs for hazardous drugs:

• Use compatible CSTD components end-to-end as trained.
• Do not “jury-rig” open needle-to-hub connections to save time.
• Still wear PPE—CSTDs reduce but do not eliminate all risk or replace gloves/gowns.

Priming, spiking, and disconnection

• Prefer pharmacy priming of hazardous infusions when available.
• If nursing primes, use closed techniques and PPE; never prime into a sink or trash without containment policy.
• Clamp and disconnect with CSTD technique; manage residual drug in tubing as hazardous waste.

Independent double-check and order verification

Chemotherapy is a high-alert medication class. Independent double-check (two qualified clinicians verifying separately) typically includes:

• Right patient (two identifiers) and consent/regimen documentation as required
• Right drug, dose (including mg/m² or AUC calculations verified against order), route, diluent, volume
• Right rate and pump programming
• Sequence in multi-agent regimens (some drugs must precede others for efficacy or toxicity reasons)
• Allergies, premedications given, labs within treatment parameters (e.g., ANC, platelets, renal/hepatic function per protocol)
• Device appropriateness for vesicant status

Exam trap: “I checked the label once while the other nurse watched” is not an independent double-check. Each person verifies against the order independently.

Multi-agent regimen sequencing (high-level)

Oncology orders often specify sequence (e.g., taxane before or after platinum depending on regimen design, hydration before nephrotoxic agents, mesna timing with ifosfamide/cyclophosphamide in selected protocols). Nursing responsibilities:

• Follow the written sequence on the treatment plan—do not improvise “whichever bag is ready first.”
• Confirm premedications (antihistamines, steroids, antiemetics, H2 blockers) completed on time.
• Coordinate hydration and rescue agents when ordered (e.g., mesna, leucovorin concepts at high level).
• Document start/stop times accurately—sequence and dwell times matter for some protocols.

CRNI does not require memorizing every regimen acronym, but it does expect you to respect sequence orders and escalate conflicts between bags and the written plan.

IV push vs infusion differences (high-level)

Oral antineoplastic adherence is important clinically but is not the focus of this infusion domain section—focus on parenteral verification, access, and acute monitoring.

Extravasation emergency

Extravasation = vesicant (or highly damaging agent) leaking into extravascular tissue.

Immediate actions (framework)

1. Stop the infusion immediately—do not flush the line with more drug.
2. Do not remove the catheter yet if protocol directs attempted aspiration of residual drug through the existing catheter.
3. Aspirate residual drug if ordered/possible; then remove catheter per protocol after aspirate step.
4. Mark the affected area, assess extent, photograph per policy, elevate extremity as directed.
5. Notify provider/rapid oncology response; obtain extravasation orders (antidotes, thermal measures).
6. Thermal strategy is drug-specific (some extravasations use cold, some heat—know where to look, do not guess).
7. Document thoroughly; arrange follow-up; patient teaching on progressive pain, blistering, color change.

Exam trap: Continuing the infusion “just a few more minutes” after burning pain, or flushing vigorously to “clear the line,” worsens tissue injury.

Hypersensitivity and infusion reactions

Taxanes (e.g., paclitaxel, docetaxel) and platinum agents (e.g., carboplatin, oxaliplatin, cisplatin) are classic for infusion reactions / hypersensitivity. Reactions range from flushing and urticaria to anaphylaxis with bronchospasm and hypotension.

Recognition

• Flushing, rash, pruritus, chest/back pain
• Dyspnea, wheezing, throat tightness
• Hypotension, tachycardia, anxiety, sense of doom
• Oxaliplatin-related cold-triggered dysesthesias (distinct teaching point—avoid cold exposure teaching)

Immediate nursing response

1. Stop the infusion (keep IV access with non-drug fluid if ordered).
2. Call for help / rapid response as severity warrants.
3. Assess ABCs; oxygen as needed; crash cart readiness.
4. Administer emergency medications as ordered/protocol (e.g., antihistamines, corticosteroids, epinephrine for anaphylaxis per emergency protocol).
5. Do not restart until provider assessment and protocol allow; rechallenge decisions are medical, not unilateral nursing improvisation.
6. Document timing, dose received, symptoms, interventions, response.

Premedication reduces but does not eliminate risk—first doses and re-exposures both deserve vigilance, especially early in the infusion.

Nadir, myelosuppression, and infection risk

Many cytotoxic agents suppress bone marrow. The nadir is the period of lowest blood counts (often days to ~1–2 weeks post-cycle depending on agent—know regimen-specific teaching). Clinical implications for infusion practice:

• Neutropenia → infection risk; fever is an emergency in the neutropenic patient.
• Thrombocytopenia → bleeding risk with invasive procedures and traumatic sticks.
• Anemia → fatigue, tachycardia, reduced reserve.

Infusion-nurse actions:

• Scrupulous aseptic technique and CLABSI prevention for central lines during immunosuppression.
• Avoid unnecessary venipuncture when possible; coordinate labs.
• Reinforce patient teaching: fever reporting thresholds, avoid crowds/sick contacts as advised, oral care, skin integrity.
• Do not hang products or flush with compromised technique “because the patient looks well.”

Integrated mini-scenarios

Scenario A — Peripheral vesicant doubt: Continuous doxorubicin is ordered via a short peripheral IV in the hand. Escalate before hang; continuous anthracycline vesicants typically require reliable central access per standards/policy.

Scenario B — Burning during infusion: Patient reports burning at a peripheral site during a vesicant. Stop immediately; do not flush more drug; follow extravasation protocol (aspirate if directed, mark, notify, antidote/thermal per drug).

Scenario C — Taxane reaction: Five minutes into paclitaxel, patient develops flushing, dyspnea, and hypotension. Stop infusion, support ABCs, give emergency meds per protocol, do not restart without provider direction.

Scenario D — PPE shortcut: Nurse hangs chemo with single non-chemo gloves and open spiking technique. Incorrect—use chemo-rated PPE and CSTD/closed technique per USP <800> principles and policy.

High-yield exam traps

• Treating all chemo as equal tissue risk (missing vesicant designation)
• Using a midline or weak peripheral for continuous vesicant therapy
• Skipping independent double-check or sequence verification
• Flushing through a suspected extravasation
• Restarting after hypersensitivity without assessment/orders
• Handling hazardous drugs without PPE/CSTD discipline
• Ignoring nadir infection risk and line-care excellence during neutropenia
• Confusing irritant phlebitis with “always continue at all costs”